MedTrace Logo

Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy

NCT00381719 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2008-01-07

No results posted yet for this study

Summary

This study will explore the safety and effectiveness of different doses of AGN 203818 in treating pain in patients with painful diabetic peripheral neuropathy

Conditions

  • Diabetic Neuropathy, Painful

Interventions

DRUG

AGN 203818

3 mg Capsule twice daily for 4 weeks

DRUG

AGN 203818

20 mg Capsule twice daily for 4 weeks

DRUG

AGN 203818

60 mg Capsule twice daily for 4 weeks

DRUG

placebo capsule

Capsule twice daily for 4 weeks

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2007-11-30
Completion
2007-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00381719 on ClinicalTrials.gov